• Who we are
    • About us
    • Our values
    • Environmental, social & governance
    • Therapeutic areas
  • What we do
    • Consulting (Acsel Health)
    • HEOR & market access
    • Scientific communications
    • Patient engagement
  • Insights
  • News & Events
  • Join us
    • Careers
    • Reasons to join
  • Contact us
  • Menu Menu

Publication Library / Publications

Cost-effectiveness analysis of saxagliptin as oral triple therapy (with metformin and a sulfonylurea) in the management of type 2 diabetes in Spain

Objectives

To evaluate the cost-effectiveness of saxagliptin versus sulfonylurea (glipizide) added to metformin in patients with type 2 diabetes mellitus (T2DM) from a US payer perspective.

Study Design

Data from a 52-week randomized controlled trial comparing saxagliptin and glipizide in combination with metformin were used in a simulation model to estimate long-term health outcomes in a cohort of T2DM patients. 

Methods

Evidence from a clinical trial and other published literature were used to assess disease progression rates and associated healthcare costs. Subjects were simulated in yearly time increments, and the model estimated the 5-year and lifetime (ie, 40-year) clinical and economic outcomes, taking into account the cost and disutility associated with weight gain and hypoglycemia events. The model estimated the incidence of microvascular and macrovascular complications, diabetes-specifi c mortality, all-cause mortality, and costs and quality-adjusted life-years (QALYs) associated with the treatment strategies. 

Results

The analysis suggests that compared with glipizide plus metformin the 5-year QALY gain for saxagliptin plus metformin was 0.53 with a cost of $13,374 per QALY. At 40 years, lifetime QALY gain for saxagliptin plus metformin rose to 2.64 per patient and cost per QALY was reduced to $1052. Sensitivity analysis indicated disutility values were a key driver, whereas the impact of overall costs was more modest. 

Conclusions

Over a T2DM patient’s lifetime, addition of saxagliptin to metformin is associated with improvement in QALYs when considering cost and disutility due to treatment side effects. Cost effectiveness is within acceptable cost-effectiveness threshold in the United States.

Authors J Sánchez-Covisa, J Franch, D Mauricio, N López-Martínez, L-H Chuang, M Capel
Journal Pharmacoeconomics - Spanish Research Articles
Therapeutic Area Endocrinology and metabolism
Center of Excellence Health Economic Modeling & Meta-analysis
Year 2016
Read full article

Services

  • Consulting
  • HEOR & market access
  • Scientific communications
  • Creative communications
  • Patient engagement

Company

  • About Us
  • Our values
  • Environmental, social & governance
  • Our commitment to rare disease
  • Careers
  • Reasons to join
  • News & insights
  • Events
  • Locations & contact

Legal and Governance

  • Terms of use
  • Privacy notice
  • Cookie policy
  • IT security measures
  • Modern slavery statement
  • Disclosure UK – ABPI
  • Looking for OpenHealth Company?
  • Legal statements & documents
  • Global ethical business conduct code
  • Suppliers
footer-logo-mark
  • Twitter
  • Linkedin
  • Instagram
  • Facebook

© Copyright OPEN Health 2025. All rights reserved. OPEN Health is a registered trademark.

backtotop-arrow
Scroll to top